ArticleCureus2025
Role of Anti-coagulation in Lemierre's Syndrome With Empyema.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lemierre's syndrome (LS) is a rare and potentially life-threatening condition that arises as a complication of oropharyngeal infections, characterized by internal jugular vein thrombosis and septicemia. This report describes a rare case of a 26-year-old previously healthy man with typical manifestations mentioned above and additionally with empyema. Management approach was multidisciplinary inputs comprised of antibiotics and surgical measures including anti-coagulation under a specialist's opinion; nonetheless, it has been a debated issue. The patient improved clinically with normalization of inflammatory markers and radiological resolution of the effusion. He was discharged with a six-week antibiotic course and transitioned to rivaroxaban. This case highlights the importance of early recognition and multidisciplinary management of LS with thoracic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.